July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02
Apr 8, 2024, 16:01

Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:

Trastuzumab Deruxtecan now FDA approved for pan-tumor with HER2 IHC3 and solid tumors who have received prior systemic treatment and have no alternative treatment options.

Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:

  • Dose 5.4 mg/kg
  • Common AE: fatigue, decreased counts and nausea. ILD can be fatal.”

Source: Rahul Gosain/LinkedIn